Previous 10 | Next 10 |
– Patient perspectives on challenges with currently available parenteral on-demand HAE treatments explain basis for non-compliance with treatment guidelines – – Global prevalence of normal C1-inhibitor HAE (HAE-nC1-INH) may be greater than previously realized ȁ...
- Study completion activities underway; topline data expected early 2024 – - Largest-ever HAE clinical trial meets on-treatment attack target – - NDA submission remains on track for first half 2024 – KalVista Pharmaceuticals, Inc . (NASDAQ: KAL...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting of the Americ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the presentation of a novel analysis characterizing hereditary angioedema (HAE) attacks ...
2023-10-01 00:05:36 ET Summary KalVista Pharmaceuticals is positioned to disrupt the HAE treatment landscape with its oral therapy, sebetralstat, offering rapid symptom relief and improved patient adherence. Financially, KalVista has a cash runway of about 14 months, but rising G&...
2023-09-07 06:32:03 ET More on KalVista Pharmaceticals Seeking Alpha’s Quant Rating on KalVista Pharmaceticals Historical earnings data for KalVista Pharmaceticals Financial information for KalVista Pharmaceticals For further details see: KalVista ...
- Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout on Track for Q4 - - Preparations Continue for NDA filing H1 2024 and Rapid Commercialization Upon Approval - KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharma...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 HAEi Regional Conference EMEA meeting t...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today the appointment of Nicole Sweeny as Chief Commercial Officer. This press release fea...
– Real-world data show people with HAE consistently recognize onset of attacks and understand the need for early attack treatment - – When provided similar efficacy and safety profiles for oral and injectable on-demand treatments for HAE attacks, adults and adolescents exp...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...